The deal adds a revenue-generating orphan drug with $8.1M in trailing sales at a modest upfront cost, expanding Eton's commercial portfolio to 11 products. Watch for September 26, 2026 launch and next quarterly update for initial prescription trends. The 55% net sales royalty is high but supplier covers all product costs, making this a capital-light revenue addition.
Price Chart
Executive Summary
Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), an FDA-approved orphan drug for leishmaniasis. Eton will pay $4.25M in fixed fees through 2030 plus up to $4.0M in sales milestone payments, and will pay the supplier 55% of net sales up to $7.0M/year and 50% above that. 2025 U.S. sales of IMPAVIDO were $8.1M. The deal adds a sixth 2026 product launch to Eton's rare disease portfolio with commercialization starting September 26, 2026.
Key Financial Metrics
Key Facts
- Eton acquired exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from an affiliate of Knight Therapeutics
- IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis
- Fixed fees total $4.25M through 2030, with payments starting at $125K on July 1, 2026
- Up to $4.0M in additional milestone payments at cumulative net sales thresholds of $50M, $100M, $150M, and $200M
- Eton pays supplier 55% of net sales up to $7.0M/year and 50% above $7.0M/year
- Supplier responsible for all product costs and regulatory expenses; Eton responsible for sales and marketing
- 2025 U.S. sales of IMPAVIDO were $8.1M per Symphony Health data
- Exclusive commercialization rights begin September 26, 2026
- Eton has option for up to ten additional annual renewals after initial term ending March 31, 2032
Financial Impact
Upfront commitment of $4.25M in fixed fees plus up to $4.0M in sales milestones; 2025 U.S. sales of $8.1M provide baseline revenue potential. At current run-rate, Eton would retain ~$3.6M annually after supplier payments, growing if sales exceed $7.0M threshold.
Risk Factors
- Leishmaniasis is a rare disease with limited patient population; sales growth may be constrained by epidemiology
- 55% net sales royalty to supplier is high, limiting margin expansion unless sales significantly exceed $7.0M/year
- Milestone payments at $50M cumulative sales may take years to trigger given current $8.1M run-rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017799 |
| Exhibit: ex_964501.htm | 0001437749-26-017799 |
| Document: 0001437749-26-017799-index-headers.html | 0001437749-26-017799 |
| Document: 0001437749-26-017799-index.html | 0001437749-26-017799 |
| Document: 0001437749-26-017799.txt | 0001437749-26-017799 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $50.75 (−4.03%) |
Oct 6, 2026 20d ago | 144 | $54.88 | awaiting T+60 | — | $50.75 (−7.53%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $50.75 (−14.24%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $50.75 (−16.02%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $50.75 (−16.03%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $50.75 (+19.51%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $50.75 (+17.45%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $50.75 (+10.40%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $50.75 (+10.40%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $50.75 (+10.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers